1376

Biometrical Journal 58 (2016) 6, 1376‚Äì1389

DOI: 10.1002/bimj.201500098

Bayesian model selection in logistic regression for the detection of
adverse drug reactions
Matthieu Marbac1 , Pascale Tubert-Bitter1 , and Mohammed Sedki‚àó,1,2
1
2

Inserm, UMR 1181 B2PHI, Institut-Pasteur and UniversiteÃÅ Versailles St-Quentin, France
FaculteÃÅ de meÃÅdecine, UniversiteÃÅ Paris-Sud, France

Received 28 May 2015; revised 21 December 2015; accepted 18 January 2016

Spontaneous adverse event reports have a high potential for detecting adverse drug reactions. However,
due to their dimension, the analysis of such databases requires statistical methods. In this context,
disproportionality measures can be used. Their main idea is to project the data onto contingency tables in
order to measure the strength of associations between drugs and adverse events. However, due to the data
projection, these methods are sensitive to the problem of coprescriptions and masking effects. Recently,
logistic regressions have been used with a Lasso type penalty to perform the detection of associations
between drugs and adverse events. On different examples, this approach limits the drawbacks of the
disproportionality methods, but the choice of the penalty value is open to criticism while it strongly
influences the results. In this paper, we propose to use a logistic regression whose sparsity is viewed as
a model selection challenge. Since the model space is huge, a Metropolis‚ÄìHastings algorithm carries
out the model selection by maximizing the BIC criterion. Thus, we avoid the calibration of penalty or
threshold. During our application on the French pharmacovigilance database, the proposed method
is compared to well-established approaches on a reference dataset, and obtains better rates of positive
and negative controls. However, many signals (i.e., specific drug‚Äìevent associations) are not detected by
the proposed method. So, we conclude that this method should be used in parallel to existing measures
in pharmacovigilance.
Code implementing the proposed method is available at the following url: https://
github.com/masedki/MHTrajectoryR.

Keywords: Bayesian Information Criterion; Binary data; Logistic regression;
Metropolis‚ÄìHastings algorithm; Model selection; Pharmacovigilance;
Spontaneous reporting.



Additional supporting information including source code to reproduce the results
may be found in the online version of this article at the publisher‚Äôs web-site

1 Introduction
To obtain approval, drugs go through many premarket safety tests, but adverse drug reactions may not
be detected during these experiments. Many national or international regulatory agencies have thus
introduced pharmacovigilance systems collecting spontaneously reported adverse events. Postapproval
drug safety surveillance relies on these reported cases for suspecting that some drugs induce adverse
events. They provide huge binary databases that describe each individual by its drug consumption
and its adverse events. Although spontaneous reporting systems suffer from many biases (Almenoff
et al., 2007), they have permitted early identification of associations between drugs and adverse events
(Szarfman et al., 2002). In order to assist pharmacovigilance experts in managing such databases,
‚àó Corresponding

author: e-mail: mohammed.sedki@u-psud.fr, Phone: +33 145 595 214


C 2016 WILEY-VCH Verlag GmbH & Co. KGaA, Weinheim

Biometrical Journal 58 (2016) 6

1377

statistical methods aiming to put the light on unexpected associations have been proposed. This is
referred to as signal detection where detected signals warrant further investigation.
The most classical methods are based on disproportionality measures and use data projections onto
contingency tables. Among them, the most popular are: the Proportional Reporting Ratio (Evans et al.,
2001), the Reporting Odds Ratio (Van Puijenbroek et al., 2002), the Bayesian Confidence Propagation
Neural Network (Bate et al., 1998), and the Gamma Poisson Shrinkage (DuMouchel, 1999). All
of these methods use a specific statistic that requires a threshold for detecting associations between
drugs and adverse events. The disproportionality measure is computed for each drug‚Äìevent pair in the
database and compared to the threshold. Moreover, the data projections onto the contingency tables
provide good computational performances. However, these projections involve some weakness against
the problems of coprescriptions and masking effects from highly reported associations for some drugs
(Caster et al., 2010). None of these methods is defined as the reference approach. Due to the shortage
of the gold standard sets, their comparison remains a challenging issue.
The shrinkage logistic regression is an interesting alternative to the methods based on data projections
onto contingency tables. In this spirit, Caster et al. (2010) propose to model the probability of an
adverse event conditionally on the drug consumptions by a sparse logistic regression whose sparsity
is imposed by a Lasso type penalty (Tibshirani, 1996). In this context, drug j and adverse event h
are claimed to be associated and to constitute a signal when the coefficient related to drug j in the
regression of adverse event h is strictly positive ‚Äî since, in this case, the adverse event occurs more
often with the consumption of this drug. However, the choice of the penalty value is a crucial and very
difficult task. Indeed, the penalty value directly influences the signal detection. Caster et al. (2010)
propose to use the same penalty for all the regressions. Moreover, they set the penalty value in order
to obtain the same number of signals as a disproportionality method. A more rigorous method, but
more computationally demanding, could consist in setting the penalty value by cross-validation where
the penalty is set for minimizing the misclassification error. However, as shown during our numerical
application, this approach obtains poor results notably due to the database sparsity. Recently, Harpaz
et al. (2013) have used a full logistic regression in a two-step procedure where the first step consists in
empirically selecting a subset of candidate drugs.
In this paper, the signal detection is performed by a model selection step that avoids the use of any
threshold or the calibration of the penalty. In this context, a model of a logistic regression determines
the coefficients that are not zero. In a Bayesian framework, the best model has the highest posterior
probability but this amount is not explicit. It is also useful to approximate its logarithm by the
Bayesian Information Criterion (Schwarz, 1978). Therefore, the signal detection consists in selecting
the model that maximizes the BIC criterion. Unfortunately, the number of competing models is too
huge for applying an exhaustive approach that computes the BIC criterion for each competing model.
Therefore, the model selection is carried out by a Metropolis‚ÄìHastings algorithm (Robert and Casella,
2004) that performs a random walk through the models of interest. This algorithm is classically used
for finding the maximum of a function even on a discrete space. In our context, the mode of its
stationary distribution corresponds to the model maximizing the BIC criterion. Thus, we were able to
develop an efficient algorithm by taking advantage of some features of the data.
In this paper, we compare our model-based procedure to the four disproportionality methods
implemented in the R package PhViD and to the Lasso logistic regression implemented in the R package
glmnet. We use the database arisen from the French pharmacovigilance that received roughly 20,000
suspected adverse drug reactions per year from 2000 to 2010. Comparison between pharmacovigilance
procedures is a difficult task. In this paper, we focus on the four adverse events described in the
Observational Medical Outcomes Partnership (OMOP) reference set (Ryan et al., 2013) and on their
145 relating drugs. To our knowledge, it is the only reference set recently formed with positive and
negative controls to address the issue of methods assessment in pharmacovigilance.
This article is organised as follows. Section 2 presents the parsimonious version of the logistic
regression. Section 3 introduces the Metropolis‚ÄìHastings algorithm devoted to the model selection.


C 2016 WILEY-VCH Verlag GmbH & Co. KGaA, Weinheim

www.biometrical-journal.com

1378

M. Marbac et al.: Bayesian model selection in logistic regression for the detection

Section 4 compares the proposed method to four disproportionality methods and to the Lasso logistic
regression. Section 5 discusses the limitations and scope of the proposed approach.

2 Parsimonious logistic regression
2.1

Spontaneous reporting database

Spontaneous reporting databases describe n individuals by their consumptions of p drugs and by
the presence or absence of d adverse events. For the purpose of logistic regression, in this article,
we consider one adverse event at a time that we denote by the binary vector y = (y1 , . . . , yn ) ‚àà Bn
where B = {0, 1}. More specifically, yi = 1 if individual i suffers from this adverse event and yi = 0
otherwise. In the regression context, explanatory variables x = (x1 , . . . , xn ) indicate the presence or the
absence of drug consumptions. Binary vector xi = (xi1 , . . . , xip ) ‚àà B p indicates the drug consumption
of individual i since xi j = 1 if individual i takes drug j and xi j = 0 otherwise.
2.2

Logistic regression

The probability of the adverse event given the drug consumption is assumed to follow a logit regression.
Model Œ≥ = (Œ≥1 , . . . , Œ≥ p ) ‚àà B p defines which drugs influence the appearance of the adverse event, since
Œ≥ j = 1 if the coefficient of the regression related to drug j is unconstrained (i.e., defined on R) while
Œ≥ j = 0 if this coefficient is zero. The indices of the drugs having a nonzero (respectively zero) coefficient
are grouped into the set DŒ≥ = { j : Œ≥ j = 1} (respectively DŒ≥c = { j : Œ≥ j = 0}).
For model Œ≥, the logit relationship is

P(yi = 1 | xi , Œ≥, Œ≤)
= Œ≤0 +
ln
Œ≤ j xi j ,
(1)
1 ‚àí P(yi = 1 | xi , Œ≥, Œ≤)
j‚ààD
Œ≥



Œ≤ = Œ≤0 , Œ≤1 , . . . , Œ≤ p ‚àà Œ≥ being the vector of regression coefficients for which many coefficients are
constrained by Œ≥ to be zero, since


Œ≥ = Œ≤ ‚àà R p+1 : ‚àÄ j ‚àà DŒ≥c , Œ≤ j = 0 .
(2)
Thus, the drugs suspected to induce the adverse event are those belonging to DŒ≥ and having a positive
coefficient in the regression (i.e., Œ≤ j > 0). Thus, we call signal each pair adverse-event/drug where the
coefficient related to the drug in the regression of the adverse event is strictly positive.
Assuming that spontaneous reports consists of n i.i.d. observations, the adverse event log-likelihood
related to model Œ≥ is written as
‚éõ
‚éû
‚é°
‚éõ
‚éû‚é§
n



 
n y | x, Œ≥, Œ≤ =
yi ‚éùŒ≤0 +
Œ≤ j xi j ‚é† ‚àí ln ‚é£1 + exp ‚éùŒ≤0 +
Œ≤ j xi j ‚é†‚é¶ .
(3)
i=1

j‚ààDŒ≥

j‚ààDŒ≥

Obviously, the indices of xi impacting the log-likelihood value are those belonging to DŒ≥ . In practice,
it is often more numerically efficient to compute the adverse event log-likelihood by using the unique
profiles of observations impacting the likelihood. This weighted form of the log-likelihood is described
in Appendix A.
From the database, the Maximum Likelihood Estimate (MLE) 
Œ≤Œ≥ is defined by



(4)
Œ≤Œ≥ = arg max Œ≤‚àà n y | x, Œ≥, Œ≤ .
Œ≥

To assess (4), we need to solve the derivative likelihood equations using the classical Newton‚ÄìRaphson
method (see Nocedal and Wright, 2006). However, the MLE is well defined only if the overlapping

C 2016 WILEY-VCH Verlag GmbH & Co. KGaA, Weinheim

www.biometrical-journal.com

Biometrical Journal 58 (2016) 6

1379

conditions of Silvapulle (1981) are satisfied (see also the discussion of Owen and Roediger, 2014).
Thus, for the binary variables, the MLE is well defined only if
‚àÄ(hy , hx ) ‚àà B2 , ‚àÄ j ‚àà DŒ≥ , ‚àÉi ‚àà Ih : xi j = hx ,

(5)

y

where Ih = {i : yi = hy }. In a few words, (5) is equivalent to have at least one absence and one presence
y
of drug consumption in both sets {xi j | yi = 0} and {xi j | yi = 1}. To ensure that the MLE is well
defined, this condition suggests not take into account drugs that do not satisfy it.

3 Model selection by MCMC algorithm
3.1

Bayesian model selection

We define the set of the competing models  as the set of models Œ≥ ‚àà B p where (5) is satisfied. So,
 = {Œ≥ ‚àà B p such as (5) is satisfied for Œ≥}.

(6)

framework, the aim is to obtain the model having the highest posterior distribution
 In a Bayesian

p Œ≥ | y, x . We assume that uniformity holds for the prior distribution p(Œ≥ | x) of models Œ≥ ‚àà . So,
we have


p Œ≥ | y, x ‚àù p(y | x, Œ≥ ),
(7)
where p(y | x, Œ≥ ) is the integrated likelihood defined by

p(y | x, Œ≥, Œ≤)p(Œ≤ | x, Œ≥ )dŒ≤,
p(y | x, Œ≥ ) =

(8)

Œ≥



where p(y | x, Œ≥, Œ≤) = exp n (y | x, Œ≥, Œ≤) is the likelihood related to model Œ≥ and where p(Œ≤ | x, Œ≥ ) is
the prior distribution of Œ≤ whose the support is included in Œ≥ . Since logarithm is monotone,


(9)
arg max Œ≥‚àà p Œ≥ | y, x = arg max Œ≥‚àà ln p(y | x, Œ≥ ).
When the integrated likelihood has not a closed form, the Bayesian Information Criterion (BIC) is
generally used. It is based on a second degree Laplace approximation of the logarithm of the integrated
likelihood (Schwarz, 1978), and it is defined as

 ŒΩŒ≥
ln n,
(10)
Œ≤Œ≥ ‚àí
BIC(Œ≥ ) = n y | x, Œ≥, 
2

where ŒΩŒ≥ = 1 + pj=1 Œ≥ j denotes the degree of freedom for model Œ≥. Therefore, we want to achieve Œ≥ 
that is the model maximizing the BIC criterion, so
Œ≥  = arg max Œ≥‚àà BIC(Œ≥ ).

(11)

This criterion selects the model providing the best trade-off between its accuracy related to the data
and its complexity.
Obviously, the number of competing models is too huge for applying an exhaustive approach (i.e., to
compute the BIC criterion for each model). Therefore, the Metropolis‚ÄìHastings algorithm described
in the following section is used to estimate Œ≥  .
3.2

Metropolis-Hastings algorithm for achieving Œ≥ 

Model Œ≥  can be achieved through a Metropolis‚ÄìHastings algorithm (Robert and Casella, 2004),
described in Algorithm 1, which performs
a random walk over . The unique invariant distribution of

Algorithm 1 is proportional to exp BIC(Œ≥ ) . Therefore, Œ≥  is the mode of its stationary distribution.

C 2016 WILEY-VCH Verlag GmbH & Co. KGaA, Weinheim

www.biometrical-journal.com

1380

M. Marbac et al.: Bayesian model selection in logistic regression for the detection

At each iteration, the algorithm proposes to move into a neighborhood of the current model. A
neighboring model is defined as copy of the current model where just a few elements are altered. Thus,
at iteration [r], the candidate Œ≥ÃÉ is equal to the current model Œ≥ [r] except for Œ± ‚â• 1 elements at the
maximum. More specifically, Œ≥ÃÉ is uniformly sampled in VŒ± (Œ≥ [r] ) where
‚éß
‚é´
p
‚é® 
‚é¨
[r]
|Œ≥ j ‚àí Œ≥ j | ‚â§ Œ± .
(12)
VŒ± (Œ≥ [r] ) = Œ≥ :
‚é©
‚é≠
j=1

In the application, we set Œ± = 5 to obtain good mixing properties. The candidate Œ≥ÃÉ is accepted with a
probability equal to


exp BIC(Œ≥ÃÉ )
[r]

.
œÅ =
(13)
exp BIC(Œ≥ [r] )
Note that we define that BIC(Œ≥ ) = ‚àí‚àû for all Œ≥ ‚àà B p \ . Thus, the probability œÅ [r] is an approximation
of the Bayes factor (Kass and Raftery, 1995) between model Œ≥ÃÉ and model Œ≥ [r] . This algorithm performs
R iterations and returns the model maximizing the BIC criterion. In practice, there may be almost
absorbing states, so different initialisations of this algorithm ensure to visit Œ≥  .
Algorithm 1. Metropolis‚ÄìHasting performing the model selection
Initialisation Œ≥ [0] is uniformly sampled in .
For r = 1, . . . , R.
Candidate step: Œ≥ÃÉ is uniformly sampled in VŒ± (Œ≥ [r] ).
Acceptance/reject step: defined Œ≥ [r] with

Œ≥

[r]

=

Œ≥ÃÉ
Œ≥ [r‚àí1]

with probability œÅ [r]
otherwise

.

End For
Return arg max r=1,...,R BIC(Œ≥ [r] ).

4 Results on real data set
In this section, after presenting the French pharmacovigilance database, the proposed method is
compared to the others by using the OMOP set. Finally, specific comments are given for the proposed
method.
4.1

Data

To evaluate and compare the performances of the competing methods, we use the OMOP (Ryan et al.,
2013) reference set of test cases that contains both positive and negative controls. Four adverse events
(i.e., d = 4) were studied in this reference set: acute myocardial infarction (AMI), acute kidney injury
(AKI), acute liver injury (ALI), and upper gastro-intestinal bleeding (GIB). There are three-hundred
and ninety-nine test cases where 165 positive controls and 234 negative controls were identified across
the four adverse events of interest. More details are given by Table 1. Ryan et al. (2013) indicate that the
majority of positive controls for AKI and GIB were supported by randomized clinical trial evidence,
while the majority of positive controls for ALI and AMI were only based on published case reports.

C 2016 WILEY-VCH Verlag GmbH & Co. KGaA, Weinheim

www.biometrical-journal.com

Biometrical Journal 58 (2016) 6

1381

Table 1 Numbers of positive and negative controls for the four adverse event in the OMOP reference
set.
Control

AMI

GIB

ALI

AKI

Positive
Negative

36
66

24
67

81
37

24
64

Table 2 Numbers of positive, negative, and unknown signals for the four adverse event in the OMOP
reference set and for the 145 drugs presented in both databases (OMOP and French pharmacovigilance).
Control

AMI

GIB

ALI

AKI

Positive
Negative
Unknown

29
43
73

20
46
79

75
22
48

21
42
82

Then a positive control is a pair (drug and adverse event) that is supported by randomized clinical
trial evidence or based on published case reports whereas a negative control is not met by neither of
these methods.
Methods are compared on the data extracted from the French pharmacovigilance database where
notifications have been collected from 2000 to 2010. The studied database describes a set of n = 219,340
individuals with their adverse event notifications and their drug consumption informations concerning
p = 145 drugs mentioned on the OMOP reference set. Each individual is described by the pair (xi , yi )
detailed in Section 2.1. Therefore, 145 √ó 4 = 580 drug‚Äìevent pairs are studied, among them 145 are
positive controls (25%), 153 are negative controls (26%) and 282 have an unknown status (49%). More
details are given in Table 2. The four studied adverse events occur 495 (AMI), 4746 (GIB), 10910
(ALI), and 5234 (AKI) times in the French pharmacovigilance database.
4.2

Competing methods

Disproportionality-based methods We chose to compare our method with all the disproportionality methods implemented in the R package PhViD (Ahmed and Poncet, 2013) Thus, four
disproportionality-based methods: the Proportional Reporting Ratio (PRR), the Reporting Odds
Ratio (ROR), the Reporting Fisher Exact Test (RFET) (Ahmed et al., 2010), and the FDR-based
Gamma Poisson Shrinkage (GPS) (Ahmed et al., 2009) are considered. The specific statistics are used
with a threshold of 0.05 and are presented in Table 3. All methods are compared on the 580 drug‚Äìevent
pairs mentioned on the OMOP reference set.
Lasso-based logistic regressions The results of the Lasso method applied on logistic regressions
are obtained with the R package glmnet (Friedman et al., 2010). The penalty value is selected by
cross-validation with tenfolds to obtain the most parsimonious model among the models having best
misclassification error. This method permits to find few signals since the selected penalty implies that
only the intercept is not zero for all adverse events except one adverse event (AMI). This example
shows the difficulty for calibrating the Lasso-penalty. Indeed, the misclassification error is roughly
constant according to the penalty value. This is due to the weak rate of notifications for one adverse
event.

C 2016 WILEY-VCH Verlag GmbH & Co. KGaA, Weinheim

www.biometrical-journal.com

1382

M. Marbac et al.: Bayesian model selection in logistic regression for the detection

Table 3 Specific statistics of the disproportionality methods: statistics (Stat), minimal number of
individuals having a drug‚Äìevent pair to claim this pair as a signal (Min.) and reference (Ref.).
Method

Stat.

Min.

Ref.

PRR
ROR
RFET
GPS

p-value of rank
p-value of rank
mid-p-value
prob of H0

3
3
1
1

Evans et al. (2001)
Van Puijenbroek et al. (2002)
Ahmed et al. (2010)
Ahmed et al. (2009)

Table 4 Number of drugs respecting (5) and number of competing models for each adverse
event (||).
Adverse event

AMI

GIB

ALI

AKI

Number of drugs respecting (5)
||

66
266

97
297

123
2123

107
2107

Model-based logistic regressions For each of the four adverse events, 100 random initialisations of
Algorithm 1 with Œ± = 5 and R = 5.103 iterations have been done. The model maximizing the BIC
criterion is returned. Table 4 presents the number of competing models for each adverse event, which
corresponds to the dimension of  defined in (6).
4.3

Method comparison

Table 5 presents the rates of positive controls, of negative controls and of unknown signals detected
by all the competing methods.
The proposed method obtains the best rates of positive controls and negative controls. It detects 70
signals while the Lasso-based method finds only 13 couples. The poor results of the Lasso are explained
by the penalty values assessed by the misclassification error rate. Indeed, the resulting penalty values
constrain all the coefficients to be zero for three adverse events. All the disproportionality methods
obtain similar results. Despite that many signals are detected by these methods (between 73 and 129),
their rates of positive and negative controls are worse than those resulting from the proposed method.
Table 5 Main results obtained by the competing methods ordered by their rate of positive controls:
number of signals (NS), rate of positive controls (RPC), rate of negative controls (RNC), and rate of
unknown signals (RUS).
Method

NS

RPC

RNC

RUS

Logistic BIC (Algorithm 1)
RFET
PRR
ROR
GPS
Lasso-CV

70
114
73
120
129
13

0.54
0.51
0.51
0.50
0.48
0.46

0.01
0.06
0.10
0.07
0.07
0.08

0.45
0.43
0.40
0.43
0.45
0.46


C 2016 WILEY-VCH Verlag GmbH & Co. KGaA, Weinheim

www.biometrical-journal.com

Biometrical Journal 58 (2016) 6

1383

Table 6 General results of Algorithm 1: number of times where Œ≥  has been found (model), number
of signals (nb signals), number of positive controls, number of negative controls, computing time in
minutes required for one Markov chain realization (time), and number of unique profiles for the best
model (mŒ≥  ).
Adverse event

AMI

GIB

ALI

AKI

Model
nb signals
Positive controls
Negative controls
Time
mŒ≥ 

100
9
1
1
1
45

67
10
5
0
3
629

50
26
20
0
3
554

56
25
12
0
5
1024

Since the proposed method obtains the best rates of positive and negative controls, we conclude that
it is more precise for the signal detection. However, it finds less signals than the disproportionality
methods. So, it permits the practitioner to focus on more probably related drug‚Äìevent pairs. Moreover,
some associations detected only by the disproportionality method could be due to the coprescription
phenomenon, whereby a drug tends to be coprescribed and therefore coreported with an other drug.
Caster et al. (2010) explored this phenomenon and found that the adjustment for coreported drugs in
the regression often explains why signals are highlighted only by disproportionality methods.
4.4

Specific comments about the proposed method

Table 6 indicates the computing time obtained by an Intel(R) Xeon(R) CPU 3.00 GHz and the number
of times where the Algorithm 1 finds the best model.
The computing time has been strongly reduced by using the expression of the log-likelihood given
in Appendix A. For example, by considering the best model resulting of the adverse event AMI where
nine variables have a nonzero coefficient, the database can be reduced to mŒ≥  = 45 unique weighted
individuals (see Appendix A). Moreover, since many different initializations allow to find Œ≥  , the
number of initializations (set at 100 during the experiment) could be reduced. Finally, the list of the
detected signals are presented in Appendix B.
4.5

Specific comments about the Lasso

We have seen that the Lasso obtains poor results when the penalty is determined according to the
misclassification error. Caster et al. (2010) set the same penalty value for all the adverse events.
Moreover, they use a disproportionality measure to evaluate the number of signals and thus to deduce
the penalty value corresponding to the same number of signals.
In order to investigate the Lasso approach features, we build a sequence of penalties to obtain
different numbers of signals with the Lasso. The numbers of positive and negative controls resulting
for each penalty values are indicated by the black lines of Fig. 1. The results related to the model
maximizing the BIC criterion are indicated by red dots.
Figure 1 shows that for a penalty providing more than 70 signals (number of signals detected by the
proposed procedure), the number of negative controls resulting form the Lasso procedure increases
quickly. For the penalty providing 70 signals, the results obtained by the Lasso procedure are slightly
better to those of the proposed procedure. However, in practice, it is not doable to use these plots for
calibrating the Lasso penalty, since the nature of signals is unknown.

C 2016 WILEY-VCH Verlag GmbH & Co. KGaA, Weinheim

www.biometrical-journal.com

50

100
150
Number of signals

200

0

50

100
150
Number of signals

200

5

10

15

20

25

0

0

Number of negative controls

0

20

40

60

80

M. Marbac et al.: Bayesian model selection in logistic regression for the detection

Number of postive controls

1384

Figure 1 Rates of positive and negative controls obtained by the Lasso with different penalties (black
curve) and obtained by the model maximizing the BIC criterion (red dots).

This illustrates the difficulty and influence of penalty calibration. This is avoided by the proposed
procedure that detects signals by maximizing BIC.

5 Discussion
In this paper, we have proposed a method for analysing individual spontaneous reporting databases
that also avoids the drawbacks of the disproportionality-based measures (coprescription and masking
effects, Caster et al., 2010). The signal detection is led throughout parsimonious logistic regressions
whose sparsity degree is assessed as a model selection challenge. Therefore, we avoid the use of Lassotype method that requires the challenging calibration of penalty. The combinatorial problem of model
selection is bypassed by Metropolis‚ÄìHastings binary space sampling.
Despite to the difficulties for evaluating pharmacovigilance methods, the OMOP reference set of
Ryan et al. (2013) gives us the opportunity to compare the proposed method to the reference approaches
on real data. On these data, it appears to be relevant for the signal detection issue. Although the better
accuracy of signal detection is provided by the proposed method, some signals are not detected by
our method. Note that some positive controls are not detected by any methods due to their very few
number of notifications (e.g., couples C09AA05/ALI or L04AB02/ALI). Moreover, some positive
controls that are not detected by our method are detected by another method. Therefore, we advice
the pharmacovigilance experts to focus on the signals detected by our method. In a second time, a
complementary study could be based on the signals detected by other methods.

C 2016 WILEY-VCH Verlag GmbH & Co. KGaA, Weinheim

www.biometrical-journal.com

200 400 600 800 1000 1200

1385

0

Number of drugs

Biometrical Journal 58 (2016) 6

0

2000
4000
6000
8000 10000
Headcount of the adverse event

Figure 2 Evolution of the number of drugs verifying (5) according to the headcount of the adverse
event.
The proposed approach can manage the whole French pharmacovigilance database that consists of
n = 219,340 individual notifications, p = 2,114 drugs and d = 4,257 adverse events. We have shown
that the dimension of the model space is defined by the number of drugs verifying (5). Figure 2 presents
the evolution of this number according to the headcount of the adverse events.
In the whole database, 75% of the adverse events can be associated to less than 42 drugs. For the
adverse events that have less than 12 drugs verifying (5), we advise to use an exhaustive approach
consisting of computing the BIC criterion for each competing models in . The model selection on the
whole French pharmacovigilance database is achieved at the cost of several days of computing time.
The proposed approach can thus be used to investigate targeted adverse events. Finally, a preliminary
drug selection could provide a reducing of computing time.
Acknowledgment The authors are grateful to Ismaƒ±Ãàl Ahmed for his useful advices and Francesco Salvo for data
cleaning and preprocessing. This work was supported by The French National Agency for Medicines and Health
Products Safety (ANSM). The authors thanks the regional pharmacovigilance centers and ANSM for providing
the pharmacovigilance database dataset.

Conflict of interest
The author has declared no conflict of interest.

Appendix A: Weighted form of the adverse event log-likelihood
Obviously, the coordinates of xi impacting the log-likelihood value are those belonging to DŒ≥ . For

each observation xi , we denote by xŒ≥i ‚àà B|Œ≥| , where |Œ≥| = pj=1 Œ≥ j , the vector containing the elements
of xi impacting the log-likelihood (i.e., the vector composed with the elements of xi such as index
belongs to DŒ≥ ). Thus, for each j = 1, . . . , |Œ≥|:
‚éß
‚é´
j
‚é®
‚é¨

Œ≥
xi j = xi j with j0 = min j :
Œ≥j = j .
(A1)
0
‚é©
‚é≠
j =1


C 2016 WILEY-VCH Verlag GmbH & Co. KGaA, Weinheim

www.biometrical-journal.com

1386

M. Marbac et al.: Bayesian model selection in logistic regression for the detection

Moreover, many individual profiles (xŒ≥i , yi ) occur many times in the database. We denote by mŒ≥
the number of different profiles impacting the log-likelihood of model Œ≥. The profile i is denoted by
(xÃÉŒ≥i , yÃÉŒ≥i ) and its weight is denoted by wŒ≥i . Thus, (3) is given by
‚éõ
‚éû
mŒ≥
|Œ≥|


 
n y | x, Œ≥, Œ≤ =
wŒ≥i yÃÉŒ≥i ‚éùŒ≤0 +
Œ≤ j xÃÉŒ≥i j ‚é† +
i=1

j=1

‚é°

‚éõ

‚àí wi ln ‚é£1 + exp ‚éùŒ≤0 +

|Œ≥|


‚éû‚é§
Œ≤ j xÃÉŒ≥i j ‚é†‚é¶ ,

(A2)

j=1

where Œ≤ Œ≥j is the j-th element that is not zero in Œ≤, so for each j = 1, . . . , |Œ≥|:
‚éß
‚é´
j
‚é®
‚é¨

Œ≥j = j .
Œ≤ Œ≥j = Œ≤ j with j0 = min j :
0
‚é©
‚é≠

(A3)

j =1

In practice, it is often more numerically efficient to compute the adverse event log-likelihood by
using (A2) than by using (3).

Appendix B: Signals detected by the proposed methods
Table B1 presents the couples between a drug and an adverse event detected by the proposed method.
Drugs are given in Anatomical Therapeutic Chemical code.
Table B1

List of the signals detected by the proposed method.

Adverse event

ATC

Headcount

Œ≤j

Omop control

AMI
ALI
AMI
ALI
AKI
ALI
AMI
AMI
GIB
AMI
GIB
AKI
GIB
AKI
AKI
AKI
ALI
ALI

L03AB07
J05AE09
N02CC03
L01BB03
M01AE09
C02KX01
M01AH01
L01BC05
M01AC01
J05AF05
B01AC04
J05AF07
B01AC07
C09AA05
C09AA03
C09CA08
L02BB01
J05AG01

7
36
6
8
46
65
21
10
138
92
523
144
31
353
165
35
10
297

2.92
2.85
2.6
2.51
2.27
2.25
2.05
1.85
1.84
1.84
1.77
1.76
1.67
1.66
1.66
1.65
1.61
1.55

Unknown
Positive
Positive
Positive
Unknown
Positive
Unknown
Unknown
Positive
Unknown
Positive
Unknown
Unknown
Unknown
Positive
Positive
Positive
Positive


C 2016 WILEY-VCH Verlag GmbH & Co. KGaA, Weinheim

www.biometrical-journal.com

Biometrical Journal 58 (2016) 6

1387

Table B1 Continued.
Adverse event

ATC

Headcount

Œ≤j

Omop control

ALI
AKI
GIB
AKI
AKI
AKI
GIB
ALI
ALI
AKI
AKI
AMI
AKI
ALI
ALI
AKI
AKI
GIB
ALI
AMI
ALI
AKI
AKI
ALI
AKI
ALI
AMI
ALI
ALI
ALI
AKI
GIB
AKI
AMI
ALI
AKI
AKI
AKI
GIB
AKI
ALI
AKI
ALI
ALI
ALI

J02AC03
C09AA02
M01AE03
C09AA10
N05AD08
L04AD01
M01AE02
J01XE01
J04AB02
C09CA07
M01AE03
L04AB02
L01BA01
A03AX13
A07EC01
L01BC05
C09CA06
M01AH01
J02AC02
B01AC04
J04AC01
C09AA06
C09AA01
N03AF01
M01AE02
D01AE15
J05AF02
L03AB07
J02AC01
G03CA03
J04AB02
A12BA01
J01MA02
J05AF06
L01BA01
M04AA01
C03AA03
M01AH01
C08DB01
A12BA01
A10BF01
M01AC01
N03AG01
J01MA06
N05BA05

117
146
276
38
10
91
52
52
538
34
250
13
129
26
71
57
139
98
22
24
359
25
61
248
43
77
30
27
188
76
104
155
147
44
186
220
430
72
81
154
36
47
298
60
147

1.54
1.51
1.5
1.49
1.48
1.38
1.34
1.33
1.31
1.31
1.31
1.29
1.28
1.25
1.24
1.18
1.16
1.15
1.15
1.14
1.08
1.06
1.02
0.99
0.99
0.98
0.98
0.98
0.97
0.96
0.96
0.94
0.87
0.83
0.81
0.77
0.73
0.68
0.63
0.62
0.61
0.59
0.56
0.54
0.53

Positive
Positive
Positive
Unknown
Unknown
Positive
Positive
Positive
Positive
Positive
Positive
Unknown
Unknown
Unknown
Unknown
Unknown
Positive
Unknown
Positive
Unknown
Positive
Unknown
Positive
Positive
Positive
Positive
Negative
Positive
Positive
Unknown
unknown
positive
unknown
unknown
positive
positive
positive
unknown
unknown
unknown
unknown
positive
positive
positive
unknown


C 2016 WILEY-VCH Verlag GmbH & Co. KGaA, Weinheim

www.biometrical-journal.com

1388

Table B1

M. Marbac et al.: Bayesian model selection in logistic regression for the detection

Continued.

Adverse event

ATC

Headcount

Œ≤j

Omop control

ALI
ALI
AKI
GIB
ALI
GIB
ALI
ALI

J05AF07
M04AA01
J01MA01
C08CA01
N06AB04
C09AA05
M01AE03
J01MA02

177
216
109
126
117
148
200
202

0.49
0.45
0.43
0.37
0.36
0.35
0.31
0.31

positive
positive
unknown
unknown
unknown
unknown
unknown
positive

References
Ahmed, I. and Poncet, A. (2013). PhViD: An R Package for PharmacoVigilance Signal Detection. R package
version 1.0.6.
Ahmed, I., Haramburu, F., Fourrier-ReÃÅglat, A., Thiessard, F., Kreft-Jais, C., Miremont-SalameÃÅ, G., BeÃÅgaud, B.
and Tubert-Bitter, P. (2009). Bayesian pharmacovigilance signal detection methods revisited in a multiple
comparison setting. Statistics in Medicine 28, 1774‚Äì1792.
Ahmed, I., Dalmasso, C., Haramburu, F., Thiessard, F., BroeÃàt, P., and Tubert-Bitter, P. (2010). False discovery
rate estimation for frequentist pharmacovigilance signal detection methods. Biometrics 66, 301‚Äì309.
Almenoff, J., Pattishall, E., Gibbs, T., DuMouchel, W., Evans, S., and Yuen, N. (2007). Novel statistical tools for
monitoring the safety of marketed drugs. Clinical Pharmacology and Therapeutics 82, 157‚Äì166.
Bate, A., Lindquist, M., Edwards, I., Olsson, S., Orre, R., Lansner, A., and De Freitas, R. (1998). A Bayesian neural
network method for adverse drug reaction signal generation. European Journal of Clinical Pharmacology 54,
315‚Äì321.
Caster, O., NoreÃÅn, G., Madigan, D., and Bate, A. (2010). Large-scale regression-based pattern discovery: the
example of screening the who global drug safety database. Statistical Analysis and Data Mining: The ASA
Data Science Journal 3, 197‚Äì208.
DuMouchel, W. (1999). Bayesian data mining in large frequency tables, with an application to the FDA spontaneous reporting system. The American Statistician 53, 177‚Äì190.
Evans, S., Waller, P., and Davis, S. (2001). Use of proportional reporting ratios (prrs) for signal generation from
spontaneous adverse drug reaction reports. Pharmacoepidemiology and Drug Safety 10, 483‚Äì486.
Friedman, J., Hastie, T., and Tibshirani, R. (2010). Regularization paths for generalized linear models via coordinate descent. Journal of Statistical Software 33, 1‚Äì22.
Harpaz, R., DuMouchel, W., LePendu, P., Bauer-Mehren, A., Ryan, P., and Shah, N. (2013). Performance
of pharmacovigilance signal-detection algorithms for the FDA adverse event reporting system. Clinical
Pharmacology and Therapeutics 93, 539‚Äì546.
Kass, R. E. and Raftery, A. E. (1995). Bayes factors. Journal of the American Statistical Association 90, 773‚Äì795.
Nocedal, J. and Wright, S. (2006). Numerical Optimization. Springer Series in Operations Research and Financial
Engineering (2nd edn.). Springer, New York, NY .
Owen, A. B. and Roediger, P. A. (2014). The sign of the logistic regression coefficient. The American Statistician
68, 297‚Äì301.
Robert, C. and Casella, G. (2004). Monte Carlo statistical methods. Springer Verlag, New York, NY.
Ryan, P., Schuemie, M., Welebob, E., Duke, J., Valentine, S., and Hartzema, A. (2013). Defining a reference set
to support methodological research in drug safety. Drug Safety 36, 33‚Äì47.
Schwarz, G. (1978). Estimating the dimension of a model. Annals of Statistics 6, 461‚Äì464.
Silvapulle, M. (1981). On the existence of maximum likelihood estimators for the binomial response models.
Journal of the Royal Statistical Society. Series B (Methodological) 43, 310‚Äì313.


C 2016 WILEY-VCH Verlag GmbH & Co. KGaA, Weinheim

www.biometrical-journal.com

Biometrical Journal 58 (2016) 6

1389

Szarfman, A., Machado, S., and Oneill, R. (2002). Use of screening algorithms and computer systems to efficiently
signal higher-than-expected combinations of drugs and events in the us FDAs spontaneous reports database.
Drug Safety 25, 381‚Äì392.
Tibshirani, R. (1996). Regression shrinkage and selection via the lasso. Journal of the Royal Statistical Society
Series B (Methodological) 58, 267‚Äì288.
Van Puijenbroek, E., Bate, A., Leufkens, H., Lindquist, M., Orre, R., and Egberts, A. (2002). A comparison
of measures of disproportionality for signal detection in spontaneous reporting systems for adverse drug
reactions. Pharmacoepidemiology and Drug Safety 11, 3‚Äì10.


C 2016 WILEY-VCH Verlag GmbH & Co. KGaA, Weinheim

www.biometrical-journal.com

